The Mycophenolate Pregnancy Registry is designed as a prospective, observational registry collecting data regarding mycophenolate exposure during pregnancy, and pregnancy outcomes, fetal and infant outcomes after exposure. Early and later term pregnancy outcomes will be solicited at selected gestational time points. Structural and functional birth defects identified in the perinatal period through one year of life will be collected and classified. This is a non-proprietary registry and is a component of a comprehensive pregnancy Risk Evaluation and Mitigation Strategy (REMS) plan required by the FDA for all mycophenolate-formulations, including CellCept, Myfortic and any generic formulations.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Maternal Outcomes: Incidence of Pregnancy Complications
Timeframe: Approximately 13 years
Fetal Outcomes: Incidence of Congenital Disorders
Timeframe: Approximately 13 years
Time/Duration of Mycophenolate Exposure
Timeframe: Approximately 13 years
Mycophenolate Dose/Regimen
Timeframe: Approximately 13 years
Indications for Mycophenolate use
Timeframe: Approximately 13 years
Maternal Medical/Demographic Characteristics
Timeframe: Approximately 13 years
Reference Study ID Number: ML22679 https://forpatients.roche.com/